methamphetamine has been researched along with nelfinavir in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ande, A; Kumar, A; Kumar, S; Li, J; Li, W; Nookala, AR; Vaidya, NK; Wang, L | 1 |
| Atluri, VSR; Jayant, RD; Kaushik, A; Nair, M; Pilakka-Kanthikeel, S; Tiwari, S; Yndart, A | 1 |
1 review(s) available for methamphetamine and nelfinavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for methamphetamine and nelfinavir
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
Topics: Amphetamine-Related Disorders; Atazanavir Sulfate; Catalytic Domain; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Inactivation, Metabolic; Lopinavir; Methamphetamine; Microsomes, Liver; Molecular Docking Simulation; Nelfinavir; Protein Binding; Pyridines; Pyrones; Sulfonamides | 2016 |
Novel nanoformulation to mitigate co-effects of drugs of abuse and HIV-1 infection: towards the treatment of NeuroAIDS.
Topics: AIDS Dementia Complex; Astrocytes; Blood-Brain Barrier; Carbazoles; Cocaine; Delayed-Action Preparations; Endothelial Cells; HIV Protease Inhibitors; HIV-1; Humans; Illicit Drugs; Magnets; Methamphetamine; Nanostructures; Nelfinavir; Neuroprotective Agents; Primary Cell Culture; Substance Abuse, Intravenous | 2017 |